DEERFIELD, Ill., June 2. Baxalta Incorporated, a wholly owned subsidiary of Baxter International Inc. Benny Goodman Greatest Hits Rar on this page. NYSE BAX, today reported continued progress on the Phase 12 open label clinical trial assessing the safety and optimal dosing level of BAX 3. IX FIX gene therapy treatment for hemophilia B, during an oral presentation at the 2. International Society on Thrombosis and Haemostasis ISTH Congress in Toronto, Canada. Best Ecu Flashing Software more. Illinois State Hemophilia Program' title='Illinois State Hemophilia Program' />36 Mins Ago Melbourne, Sydney fringes busiest, prolonging building boom. SYDNEY, Nov 15 On the edges of Sydney, where Australias biggest city is sprawling across. Updating the database of the Illinois Compiled Statutes ILCS is an ongoing process. Recent laws may not yet be included in the ILCS database, but they are found on. CAN I DONATE Most healthy adults are eligible to give blood, however, there are some reasons a person may be deferred from donating temporarily, indefinitely, or. The official website of Science Olympiad, one of the largest K12 STEM organizations in the US. Find the latest info on events competitive tournaments here. Hemophilia-genetics1.gif' alt='Illinois State Hemophilia Program' title='Illinois State Hemophilia Program' />This report provides indepth descriptions of statesponsored prescription drug subsidy and discount programs in over 40 states, most authorized or operational. DISCLAIMER The texts of rules provided in the Illinois Department of Public Health Web site are intended for the convenience of interested persons. Individuals with hemophilia B lack the ability to produce clotting factor IX and are today treated with infusions of plasma derived or recombinant factor IX. BAX 3. 35 is designed to provide a mechanism for a hemophilia B patients own liver to begin producing FIX over an extended period following a single dose of treatment. The technology Baxalta has investigated since 2. Biological Nano Particle BNP platform an advanced r. AAV8 based gene therapy technology obtained through the collaboration and subsequent acquisition of Chatham Therapeutics. The BNP platform is designed to enable patients to achieve stable factor IX activity on their own when infused in the body. To achieve a therapeutic effect while keeping vector doses as low as possible, BAX 3. FIX Padua, a naturally occurring, highly active variant of FIX. A total of seven patients in three sequentially ascending dosing cohorts have been treated in the trial with evidence of a dose related response. No patients have developed FIX inhibitors to date. Some FIX expression was observed in the lowest dosing cohort 2x. In the second dosing cohort 1x. FIX and one of these patients has had sustained FIX expression levels of 2. In the highest dose cohort 3x. FIX expression, with one patient resuming regular FIX infusions. Immune responses have been reported and managed in previous studies with gene therapy technology. Baxalta continues to address the immune responses observed while working to maintain target trough levels. Gene therapy has the potential to achieve a long term therapeutic solution for people with hemophilia and will continue to be a key focus for Baxalta, said John Orloff, MD, vice president and global head of research and development at Baxalta. We continue to advance this program as we learn more about this new concept and its value for those living with hemophilia, with an opportunity to truly transform the treatment paradigm. The clinical trial is assessing the safety of ascending doses of BAX 3. B at treatment centers in the United States. The primary endpoint is the safety of a single dose of BAX 3. Secondary endpoints include evaluation of the optimal dose to achieve stable therapeutic plasma FIX activity, as well as pharmacokinetics and immune response to treatment. Additional patients are being screened and more information on the trial is available at www. Identifier 0. 16. In April 2. 01. 4, Baxter acquired Chatham Therapeutics, LLC, an affiliate of Asklepios Bio. Pharmaceutical, Inc. Ask. Bio, and its developmental gene therapy programs. Chathams Biological Nano Particles BNP, an advanced recombinant adeno associated virus r. AAV based gene therapy technology, has shown potential therapeutic activity in early studies. In addition to the research in hemophilia B, Baxalta is also advancing plans to evaluate the gene therapy technology in the treatment of hemophilia A. A summary of the data is available here About Hemophilia BHemophilia B is the second most common type of hemophilia also known as Christmas disease and is the result of insufficient amounts of clotting factor IX, a naturally occurring protein in blood that controls bleeding. Approximately 2. 6,0. U. S., have been diagnosed with hemophilia B. Hemophilia B is often a debilitating, chronic disease with complications that include bleeding episodes, hemophilic arthropathy bleeding into a joint and hospitalization. About Baxalta. Baxalta Incorporated is a 6 billion global biopharmaceutical leader developing, manufacturing and commercializing therapies for orphan diseases and underserved conditions in hematology, oncology and immunology. Driven by passion to make a meaningful impact on patients lives, Baxaltas broad and diverse pipeline includes biologics with novel mechanisms and advanced technology platforms such as gene therapy. The Baxalta Global Innovation and R D Center is located in Cambridge, Massachusetts. Expected to launch in 2. Baxter International, Baxaltas heritage in biopharmaceuticals spans decades. Baxaltas therapies are available in more than 1. Headquartered in Northern Illinois, Baxalta employs 1. About Baxter International Inc. Baxter International Inc., through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. This release includes forward looking statements concerning a Phase III open label clinical trial of BAX 3. Baxters biopharmaceutical and medical products businesses and related research and development strategies. These statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward looking statements clinical trial results satisfaction of regulatory and other requirements actions of regulatory bodies and other governmental authorities changes in laws and regulations product quality, manufacturing or supply issues patient safety issues the ability to successfully separate the businesses on the terms or timeline currently contemplated, if at all, and achieve the intended results and other risks identified in Baxters most recent filing on Form 1. K and other SEC filings and in Baxaltas Registration Statement on Form 1. Baxters website. Baxter does not undertake to update its forward looking statements.